Management Team

David Grossman


David's extensive experience comprises venture capital, private equity and executive management, mainly in the healthcare arena.

Until 2014, David was CEO and Board Member at XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL), where he recovered the company from practically bankruptcy via M&A, in-licensing, fund raising, takeovers to being a late-stage drug development company. 

David has also served as a Vice President of Eurocom Investments LP, a private equity fund. Prior to that, Mr. Grossman was a Senior Analyst at Israel Health Care Ventures (IHCV), an Israeli leading healthcare venture capital fund.

David was Chairman of the Board at Algomizer Ltd. (TASE: ALMO) and Board member in several public companies traded on NASDAQ, AIM and TASE, such as, Rosetta Green Ltd. (TASE: GFC), Proteologics Ltd. (TASE: PRTL), InterCure Ltd. (TASE: INCR), Bio Light Israeli Life Science Investments Ltd. (TASE: BOLT), and Gilat Satcom Ltd. (AIM: GLT).

He currently serves as a board member at AIT Pharmaceuticals Ltd, Cellect Biotechnology Ltd. (NASDAQ: APOP, TASE: CLBD) and Amnis Therapeutics Ltd. (TASE: AMNS).

A native of the United Kingdom, David holds a BA in Business Administration and Finance from the Interdisciplinary Center (IDC) in Israel.